Browse Galnac Lipids in the DC Chemicals RNA Delivery catalog.
8 products currently listedResearch-use products only
Evidence noteCategory membership indicates research relevance. Organ targeting, cell specificity and performance must be verified from the formulation and study conditions cited for each product.
GL6 is a trivalent GalNAc-lipid conjugate designed for ASGPR-mediated hepatic delivery. It features a lysine-based scaffold covalently linked to three GalNAc moieties via a 36-unit PEG spacer, anchored by a 1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid tail. This structure balances ligand accessibility (via optimized PEG length) and nanoparticle stability (via hydrophobic DSG anchoring). Compared to GL3 (TRIS scaffold, same PEG length), GL6’s simplified lysine scaffold improves manufacturability. In LDLR-deficient models, GL6 enabled 61% liver editing (vs. 5% with standard LNPs) at 2 mg/kg, demonstrating superior ASGPR targeting. Its design minimizes ligand crowding (0.05 mol% surface density) while maximizing endosomal escape and durable gene editing.
Galnac Lipid 83 is developed by Prime Medicine Patent: WO2024220807.Galnac Lipid 83 83 is a GalNAc-conjugated lipid designed for targeted liver delivery. It features a triantennary GalNAc ligand linked via a PEG spacer (e.g., -(CH2CH2O)n-) to a branched hydrophobic tail (C18 alkyl chains). The structure includes amide/ester bonds for stability and a stereospecific configuration (R/S) to optimize ASGPR receptor binding. Integrated into lipid nanoparticles (LNPs), it enhances hepatic uptake of nucleic acids (e.g., mRNA, gene editors) by leveraging ASGPR-mediated endocytosis. Its design balances hydrophilicity (PEG) and lipophilicity (alkyl chains) for efficient encapsulation and in vivo delivery, supporting therapeutic applications in liver-specific gene editing or RNA therapies.
GalNAc Lipid 1002 is a trivalent GalNAc-lipid conjugate designed for ASGPR-mediated hepatic delivery. It features a lysine-based scaffold covalently linked to three GalNAc moieties via a 12-unit PEG spacer, anchored by a 1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid tail.
GalNAc Lipid 1005 is a trivalent GalNAc-lipid conjugate designed for ASGPR-mediated hepatic delivery. It features a lysine-based scaffold covalently linked to three GalNAc moieties via a 44-unit PEG spacer, anchored by a 1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid tail.
DSPE-PEG2K-triGalNAc is a polar lipid composed of DSPE and tri-N-acetylgalactosamine that can be used to construct liposomes target to asialoglycoprotein receptor (ASGPR).
Disclosed in PCT patent WO2025/240833A1 from Acuitas Therapeutics Inc., Compound I‑1 is a trivalent tri-GalNAc PEGylated targeting lipid composed of three ASGPR-binding GalNAc moieties, a PEG spacer and double C18 alkyl lipid tails that insert into LNP lipid bilayer.
DSG-PEG2K-triGalNAc is a functionalized PEG lipid that enhances targeted drug delivery by binding to the Asialoglycoprotein Receptor (ASGPR) which are predominantly found on the surface of liver cells. By functionalizing DSG-PEG2K with triGalNac, it allows this PEG lipid to be used in the formation of liposomes or LNPs that target the liver for drug delivery.
